The medical community is buzzing by retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant results in early trials . This treatment works by imitating natural hormones to impact appetite and promote feelings of fullness , ultimately resulting in noticeable fat loss . While still under evaluation and not readily available, init